|3 Months Ended|
Mar. 31, 2019
|Subsequent Events [Abstract]|
Note 11 – Subsequent Events
On April 2, 2019, the Company agreed to provide funds in the amount of $157,405 per year under a Cooperative Research and Development Agreement (“ CRADA”) to support the National Institute of Allergy and Infectious Diseases investigators in the conduct of clinical research to investigate the safety, efficacy, and pharmacokinetics of encochleated drug products in patients with fungal, bacterial, or viral infections. The term of the CRADA is three years.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef